Inhibrx Biosciences, Inc. INBX Business Segments — Clinical trials
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inbx:ResearchAndDevelopmentExpenseClinicalTrials.
The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — clinical trials.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — clinical trials?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — clinical trials of $8.83M in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s business segments — clinical trials changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — clinical trials decreased by 25.9% year-over-year, from $11.92M to $8.83M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — clinical trials?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — clinical trials has grown at a -9.3% compound annual growth rate (CAGR), from $42.96M to $35.34M.
- What does business segments — clinical trials mean?
- Captures the direct costs incurred for conducting clinical studies and trials for the segment's therapeutic candidates. It is a critical indicator of the company's investment in advancing its pipeline through regulatory development phases.